Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132342 | 0.84 | NNMT (0.59) | NNMTEPHX2HCAR3HCAR2SMN1; SMN2 | |
| SCHEMBL3129465 | 0.78 | NNMT (0.59) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL11546416 | 0.77 | HCAR3 (0.73) | NNMTEPHX2HCAR3HCAR2SMN1; SMN2 | |
| SCHEMBL3464045 | 0.77 | HPGD (0.36) | HCAR3SMN1; SMN2 | |
| SCHEMBL3465091 | 0.77 | NNMT (0.58) | NNMTEPHX2HCAR3 | |
| SCHEMBL1877716 | 0.73 | NNMT (0.65) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL5205802 | 0.73 | NNMT (0.60) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL6700940 | 0.72 | NNMT (0.59) | NNMTEPHX2HCAR3HCAR2SMN1; SMN2 | |
| SCHEMBL4320704 | 0.72 | NNMT (1.00) | NNMTEPHX2HCAR3SMN1; SMN2 | |
| SCHEMBL30492154 | 0.72 | NNMT (0.58) | NNMTEPHX2HCAR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | NNMT 1562/4885EPHX2 2057/4885HCAR3 46/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | NNMT 957/4885EPHX2 808/4885HCAR3 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.